DNLI logo

Denali Therapeutics Inc. (DNLI) EBITDA

Annual EBITDA:

-$492.89M-$312.91M(-173.87%)
December 31, 2024

Summary

  • As of today, DNLI annual EBITDA is -$492.89 million, with the most recent change of -$312.91 million (-173.87%) on December 31, 2024.
  • During the last 3 years, DNLI annual EBITDA has fallen by -$205.73 million (-71.64%).
  • DNLI annual EBITDA is now -791.78% below its all-time high of $71.25 million, reached on December 31, 2020.

Performance

DNLI EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherDNLIincome statement metrics

Quarterly EBITDA:

-$131.92M+$11.34M(+7.91%)
June 30, 2025

Summary

  • As of today, DNLI quarterly EBITDA is -$131.92 million, with the most recent change of +$11.34 million (+7.91%) on June 30, 2025.
  • Over the past year, DNLI quarterly EBITDA has dropped by -$17.27 million (-15.06%).
  • DNLI quarterly EBITDA is now -153.73% below its all-time high of $245.51 million, reached on December 31, 2020.

Performance

DNLI Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherDNLIincome statement metrics

TTM EBITDA:

-$524.51M-$17.27M(-3.40%)
June 30, 2025

Summary

  • As of today, DNLI TTM EBITDA is -$524.51 million, with the most recent change of -$17.27 million (-3.40%) on June 30, 2025.
  • Over the past year, DNLI TTM EBITDA has dropped by -$37.80 million (-7.77%).
  • DNLI TTM EBITDA is now -850.73% below its all-time high of $69.87 million, reached on December 31, 2020.

Performance

DNLI TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherDNLIincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

DNLI EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-173.9%-15.1%-7.8%
3Y3 Years-71.6%-119.2%-83.8%
5Y5 Years-140.2%-123.1%-126.7%

DNLI EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-173.9%at low-176.8%+7.9%-254.1%at low
5Y5-Year-791.8%at low-153.7%+7.9%-850.7%at low
All-TimeAll-Time-791.8%at low-153.7%+7.9%-850.7%at low

DNLI EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$131.92M(+7.9%)
-$524.51M(-3.4%)
Mar 2025
-
-$143.25M(-11.9%)
-$507.25M(-2.7%)
Dec 2024
-$492.89M(-173.9%)
-$127.99M(-5.5%)
-$494.08M(+0.5%)
Sep 2024
-
-$121.35M(-5.8%)
-$496.49M(-2.0%)
Jun 2024
-
-$114.65M(+11.9%)
-$486.71M(-143.1%)
Mar 2024
-
-$130.09M(+0.2%)
-$200.22M(-10.1%)
Dec 2023
-$179.97M(+45.5%)
-$130.40M(-16.9%)
-$181.78M(-18.4%)
Sep 2023
-
-$111.58M(-164.9%)
-$153.50M(-3.6%)
Jun 2023
-
$171.84M(+253.9%)
-$148.13M(+61.0%)
Mar 2023
-
-$111.64M(-9.3%)
-$380.15M(-13.9%)
Dec 2022
-$330.36M(-15.0%)
-$102.12M(+3.9%)
-$333.71M(-8.6%)
Sep 2022
-
-$106.21M(-76.5%)
-$307.41M(-7.7%)
Jun 2022
-
-$60.18M(+7.7%)
-$285.38M(+0.1%)
Mar 2022
-
-$65.20M(+14.0%)
-$285.54M(+1.6%)
Dec 2021
-$287.16M
-$75.81M(+10.0%)
-$290.14M(-1030.7%)
Sep 2021
-
-$84.19M(-39.5%)
$31.18M(-45.0%)
Jun 2021
-
-$60.34M(+13.6%)
$56.71M(-2.1%)
DateAnnualQuarterlyTTM
Mar 2021
-
-$69.80M(-128.4%)
$57.92M(-17.1%)
Dec 2020
$71.25M(+134.7%)
$245.51M(+518.6%)
$69.87M(+130.2%)
Sep 2020
-
-$58.65M(+0.8%)
-$231.34M(-4.7%)
Jun 2020
-
-$59.13M(-2.2%)
-$220.96M(+0.1%)
Mar 2020
-
-$57.86M(-3.9%)
-$221.15M(-8.7%)
Dec 2019
-$205.19M(-426.7%)
-$55.70M(-15.4%)
-$203.39M(-188.1%)
Sep 2019
-
-$48.27M(+18.6%)
-$70.59M(-21.8%)
Jun 2019
-
-$59.32M(-47.9%)
-$57.96M(-24.3%)
Mar 2019
-
-$40.10M(-152.0%)
-$46.63M(-48.4%)
Dec 2018
-$38.96M(+55.3%)
$77.10M(+316.4%)
-$31.41M(+76.1%)
Sep 2018
-
-$35.64M(+25.7%)
-$131.25M(-12.1%)
Jun 2018
-
-$47.98M(-92.8%)
-$117.12M(-69.4%)
Mar 2018
-
-$24.89M(-9.5%)
-$69.14M(-56.3%)
Dec 2017
-$87.06M(-1.3%)
-$22.73M(-5.7%)
-$44.24M(-9.0%)
Sep 2017
-
-$21.51M(-12.7%)
-$40.60M(+18.2%)
Dec 2016
-$85.96M(-419.2%)
-$19.09M(+37.5%)
-$49.62M(-62.5%)
Sep 2016
-
-$30.53M
-$30.53M
Dec 2015
-$16.56M
-
-

FAQ

  • What is Denali Therapeutics Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Denali Therapeutics Inc.?
  • What is Denali Therapeutics Inc. annual EBITDA year-on-year change?
  • What is Denali Therapeutics Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Denali Therapeutics Inc.?
  • What is Denali Therapeutics Inc. quarterly EBITDA year-on-year change?
  • What is Denali Therapeutics Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Denali Therapeutics Inc.?
  • What is Denali Therapeutics Inc. TTM EBITDA year-on-year change?

What is Denali Therapeutics Inc. annual EBITDA?

The current annual EBITDA of DNLI is -$492.89M

What is the all-time high annual EBITDA for Denali Therapeutics Inc.?

Denali Therapeutics Inc. all-time high annual EBITDA is $71.25M

What is Denali Therapeutics Inc. annual EBITDA year-on-year change?

Over the past year, DNLI annual EBITDA has changed by -$312.91M (-173.87%)

What is Denali Therapeutics Inc. quarterly EBITDA?

The current quarterly EBITDA of DNLI is -$131.92M

What is the all-time high quarterly EBITDA for Denali Therapeutics Inc.?

Denali Therapeutics Inc. all-time high quarterly EBITDA is $245.51M

What is Denali Therapeutics Inc. quarterly EBITDA year-on-year change?

Over the past year, DNLI quarterly EBITDA has changed by -$17.27M (-15.06%)

What is Denali Therapeutics Inc. TTM EBITDA?

The current TTM EBITDA of DNLI is -$524.51M

What is the all-time high TTM EBITDA for Denali Therapeutics Inc.?

Denali Therapeutics Inc. all-time high TTM EBITDA is $69.87M

What is Denali Therapeutics Inc. TTM EBITDA year-on-year change?

Over the past year, DNLI TTM EBITDA has changed by -$37.80M (-7.77%)
On this page